All News
Filter News
Found 809,049 articles
-
Global Food Industries reaps two topmost awards for Innovation excellence at UAE Innovation Awards 2019
2/28/2019
-
Amryt Pharma plc (“Amryt” or the “Company”) Update on AP101 EASE Phase III trial
2/28/2019
IDMC recommends study can enrol children and infants aged from 21 days to 4 years
-
Recipharm achieves new ISO 45001 certification to support sustainability efforts
2/28/2019
Recipharm, the contract development and manufacturing organisation, has achieved the new ISO 45001 certification at its Wasserburg facility in Germany.
-
Medigene AG: Medigene presents poster on in vitro evaluation of TCR efficacy and toxicity at AACR
2/28/2019
Medigene AG announced that researchers of the Company will present a poster at the 2019 American Association for Cancer Research Annual Meeting.
-
MDxHealth (R): MDxHealth Reports Financial Year 2018 Results and Provides Outlook for 2019
2/28/2019
MDxHealth SA, announced its business update and financial results for the year ended December 31, 2018 and provided its strategic outlook for 2019.
-
Althea Group Holdings Limited (ASX:AGH): Half Year Financial Report & Appendix 4D For the period ended 31 December 2018
2/28/2019
Althea Group Holdings Limited is pleased to provide its Half Year Financial Report and Appendix 4D.
-
Liquid biopsy as effective as tissue biopsy for non-small cell lung cancer according to MD Anderson study
2/28/2019
Test more accurately identifies four mutations for which FDA-approved drugs exist and offers faster turn-around time between initial testing and commencement of therapy
-
ARTEREZ Introduces a Novel, Triple-Compound Oral Therapy And Diagnostic Panels Targeting The Multi-Factorial ‘Root-Causes’ of Cardiovascular Disease – Not Cholesterol - in Human Studies
2/28/2019
Cardiovascular disease, particularly coronary heart disease, remains the No. 1 disease killer and continues to rise in the US and the world despite record numbers of statins being prescribed year after year.
-
Dr. Jonathan Rich Appointed as Lumileds Chief Executive Officer
2/28/2019
Lumileds announced the appointment of Dr. Jonathan Rich as Chief Executive Officer.
-
Amryt Pharma plc: Update on AP101 EASE Phase III trial
2/28/2019
Amryt, a revenue generating orphan drug company focused on acquiring, developing & commercialising products that help to improve the lives of patients where there is a high unmet medical need, today announces an update on its pivotal Phase III EASE trial for AP101 as a potential treatment for Epidermolysis Bullosa (“EB”).
-
Oxurion NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition for DME at 2019 EURETINA Winter Meeting
2/28/2019
Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, announces today that it will present at the 9th European Society of Retina Specialists (EURETINA) Winter Meeting, which is being held March 1-2, 2019 in Prague, Czech Republic at the Clarion Congress Hotel.
-
Sareum notes that an abstract reporting new preclinical data for SRA737 has been selected as a late-breaking oral presentation at AACR 2019
2/28/2019
Sareum Holdings plc (AIM: SAR), the specialist small molecule drug development business, notes that Sierra Oncology (“Sierra”), the licence holder advancing clinical cancer candidate SRA737, announced late yesterday that an abstract reporting preclinical data for SRA737, its Chk1 inhibitor, plus low dose gemcitabin
-
iOnctura selected for an oral presentation at 2019 AACR Annual Meeting
2/28/2019
iOnctura SA, a late stage preclinical immuno-oncology company, announced today that its abstract (abstract # 1781) entitled “Preclinical development of a novel, highly selective PI3Kδ inhibitor, IOA-244, for the treatment of solid malignancies” has been selected for an oral presentation at the American Association for Cancer Research Annual Meeting 2019 which will take place from 29th March to 3rd April in Atlanta, Georgia, USA.
-
Ergomed and PSR Orphan Experts, Ergomed’s rare disease specialist division, announce 2019 activities in support of Rare Disease Day®
2/28/2019
Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a specialised pharmaceutical services and drug development company, together with its rare disease subsidiary PSR Group BV (‘PSR Orphan Experts’), a specialised contract research organisation focusing on orphan drug development, today announced their support of this year’s Rare Disease Day® held on February 28th.
-
Spectrum Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results and Pipeline Update
2/28/2019
Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and year ended December 31, 2018.
-
Hikma establishes partnership with Melinta in MENA
2/28/2019
Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) announces an exclusive license, supply and distribution agreement with Melinta Therapeutics (Melinta), for Melinta’s intravenous and oral formulations of Baxdela
-
Nektar Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results
2/28/2019
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2018.
-
Bedfont announces multiyear ODM deal with global respiratory diagnostics company, MGC Diagnostics Corporation
2/28/2019
MGC Diagnostics Corporation (MGCD), through its Medical Graphics and Medisoft subsidiaries, is a global medical technology company dedicated to the delivery of diagnostic solutions for detecting, classifying, and managing cardiorespiratory disease
-
Mirati Therapeutics Reports Fourth Quarter Financial Results
2/28/2019
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full-year ended December 31, 2018.
-
MedAlliance Granted Breakthrough Device Designation from FDA for Sirolimus Drug-Eluting Balloon
2/28/2019
Swiss-based M.A. MedAlliance SA has been granted Breakthrough Device Designation from the US Food and Drug Administration (FDA) for SELUTION™, its sustained limus release (SLR) drug-eluting balloon (DEB) catheter, for the treatment of coronary disease.